睿昂基因2024年转亏 2021年上市募2.56亿国泰海通保荐

Core Viewpoint - Ruiang Gene (688217.SH) reported a decline in revenue and net profit for the year 2024, indicating financial challenges while maintaining positive cash flow from operating activities [1][2]. Financial Performance - The company achieved operating revenue of 242.31 million yuan in 2024, a decrease of 6.16% compared to 258.21 million yuan in 2023 [2]. - The net profit attributable to shareholders was -15.76 million yuan, a significant decline from a profit of 7.93 million yuan in the previous year, representing a decrease of 298.78% [2]. - The net profit after deducting non-recurring gains and losses was -19.25 million yuan, down from 3.70 million yuan in 2023, marking a decrease of 620.88% [2]. - The net cash flow from operating activities was 59.98 million yuan, reflecting a year-on-year increase of 33.00% from 45.10 million yuan in 2023 [1][2]. Profit Distribution - The company plans not to distribute cash dividends, issue bonus shares, or increase capital reserves for the year 2024, retaining the undistributed profit of 13.83 million yuan for future use [2]. Stock Issuance - Ruiang Gene proposed to authorize the board to issue shares to specific investors, with a financing total not exceeding 300 million yuan, which is capped at 20% of the net assets as of the end of the previous year [4].